BRIEF-Advaxis says therapy improves survival rates in cervical cancer patients
 

BRIEF-Advaxis says therapy improves survival rates in cervical cancer patients
* Says Axalimogene Filolisbac showed 38.5 percent 12-month survival in patients with persistent/recurrent metastatic cervical cancer http://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/reut...sU:V_sGLiPBpWU http://feeds.feedburner.com/~ff/reut...sU:F7zBnMyn0Lo
http://feeds.feedburner.com/~r/reute...~4/GHdjGKiGxd4